Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.48 |
| ▸ | GRM5 | P41594 | 11/20 | 0.48 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31701864 | 0.86 | GRM1 (0.48) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL63673 | 0.85 | GRM1 (0.51) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL64701 | 0.85 | GRM1 (0.55) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL28364566 | 0.85 | ALDH1A1 (0.36) | GRM1GRM5GPR119NAMPT | |
| SCHEMBL15756310 | 0.85 | GRM1 (0.55) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL15001430 | 0.84 | GRM1 (0.52) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL12740696 | 0.83 | GRM1 (0.54) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL15756312 | 0.82 | GRM1 (0.59) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL18009522 | 0.82 | GRM1 (0.53) | GRM1GRM5PDK4GPR119CYP11B2 | |
| SCHEMBL29138576 | 0.82 | GRM1 (0.53) | GRM1GRM5PDK4GPR119CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111410648-B | Chiral c-KIT inhibitor drug key intermediate and preparation method thereof | 浙江海正药业股份有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION | 2024-01-11 | — | — | US | disclosed |
| CN-117098760-A | Compositions and methods for treating KIT and PDGFRA mediated diseases | 缆图药品公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4229060-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | Blueprint Medicines Corporation (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-110891953-B | Pyrrolotriazines derivatives, preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022081627-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022081627-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT-AND PDGFRA-MEDIATED DISEASES | BLUEPRINT MEDICINES CORPORATION (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2019034128-A1 | PYRROLOTRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 浙江海正药业股份有限公司 | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240010652-A1 | COMPOSITIONS AND METHODS FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES | KIT, PDGFRA, PDGFRB | GRM1 1271/4885GRM5 1548/4885PDK4 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.